A third of people with schizophrenia have symptoms that will not sufficiently respond to two adequate trials of antipsychotic medications.1 For these people with treatment-resistant schizophrenia, ...

Talk about a heavy dose. While the bulk of news coverage is focused on GLP-1 drugs like Ozempic that cause weight loss, ...

Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

a mechanism thought to contribute to tolerability issues with the current generation of antipsychotic drugs. Cerevel is running two phase 2 trials of the once-daily oral drug – EMPOWER-1 and ...

(Peter Julian) For first-generation college students, arriving on campus represents a milestone, a triumph over considerable odds. But it’s also only a beginning, and the rest of the way isn’t ...

In fall 2024, xanomeline trospium chloride (XT) was approved by the U.S. Food and Drug Administration for the treatment of ...

New York, USA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Comprehensive Market Analysis of Latest Published Different Types of Depression Reports | DelveInsight The depression treatment market is ...

In collaboration with Massachusetts General Hospital as its contract research organization, Alzamend aims to explore the unique properties of AL001 and its effects on lithium delivery in the brain ...

a mechanism thought to contribute to tolerability issues with the current generation of antipsychotic drugs. If it does prove to be the end of emraclidine for schizophrenia, that looks set to ...

NPR's Up First is the news you need to start your day. The three biggest stories of the day, with reporting and analysis from NPR News — in 10 minutes. Available weekdays at 6:30 a.m. ET ...